Synergy with IL-12 gene therapy and anti-4-1BB antibody [127] or local 4-1BB gene [126] delivery has also been shown with significant tumor rejection and long-term immunity seen in metastatic breast and colon cancer models. This evidence concerns the gene TNFRSF9 and malignant colon neoplasm.